Abstract
Kennedy’s disease, resulted from the expansion of a CAG repeat in exon 1 of androgen receptor (AR) gene, is a motor neuron degenerative disease in the brainstem and spinal cord with the slow development of facial, bulbar, and limb muscle degeneration. To investigate the clinical manifestations and gene mutations in Han Chinese patients with Kennedy’s disease. The clinical manifestations of 5 male Han Chinese patients including 2 probands and their relatives from 2 families and 1 sporadic case were retrospectively studied. The CAG repeats in the first exon of AR were screened in 5 Han Chinese people including 2 probands and their healthy relatives from 2 families and 1 sporadic case by polymerase chain reaction (PCR) and direct sequencing. The average age at onset of Kennedy’s disease was 48.20 ± 8.70 (mean ± SD) years and the average duration was 7.60 ± 5.32 years. All the patients showed slow onset and progressive weakness, wasting, and fasciculations of the whole body. Four patients demonstrated decreased fertility and 1 patient showed mild gynecomastia. Serum creatine kinase and testosterone levels were elevated mildly in 2 and 1 patients, respectively. The electromyogram showed neurogenic abnormalities. Muscle magnetic resonance demonstrated reduced muscle volume and fatty infiltration. Three different enlarged CAG domains were discovered in the 2 families and 1 sporadic patient with Kennedy’s disease, and the CAG repeat number was 48, 43, and 44, respectively. The clinical manifestations of Kennedy’s disease in Han Chinese middle-aged men were progressive weakness and atrophy in the bulbar and spinal muscles, occasionally demonstrating incomplete androgen insensitivity syndrome. These patients were also characterized with enlarged CAG repeat number in the first exon of AR, indicating that CAG number could be used in the diagnosis of Han Chinese patients with Kennedy’s disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alves CN et al (2018) X-linked spinal and bulbar muscular atrophy (Kennedy’s disease): the first case described in the Brazilian Amazon. Einstein (Sao Paulo) 16(2):eRC4011
Banno H, Katsuno M, Suzuki K, Takeuchi Y, Kawashima M, Suga N, Takamori M, Ito M, Nakamura T, Matsuo K, Yamada S, Oki Y, Adachi H, Minamiyama M, Waza M, Atsuta N, Watanabe H, Fujimoto Y, Nakashima T, Tanaka F, Doyu M, Sobue G (2009) Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy. Ann Neurol 65(2):140–150
Breza, M. and G. Koutsis (2018) Kennedy’s disease (spinal and bulbar muscular atrophy): a clinically oriented review of a rare disease. J Neurol: p. 1–9
Caballero PE (2012) Klinefelter’s syndrome associated with progressive muscular atrophy simulating Kennedy’s disease. Ann Indian Acad Neurol 15(3):227–229
Davey RA, Grossmann M (2016) Androgen receptor structure, function and biology: from bench to bedside. Clin Biochem Rev 37(1):3–15
Fan HC, Ho LI, Chi CS, Chen SJ, Peng GS, Chan TM, Lin SZ, Harn HJ (2014) Polyglutamine (PolyQ) diseases: genetics to treatments. Cell Transplant 23(4–5):441–458
Fernandez-Rhodes LE et al (2011) Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial. Lancet Neurol 10(2):140–147
Finsterer J (2009) Bulbar and spinal muscular atrophy (Kennedy’s disease): a review. Eur J Neurol 16(5):556–561
Finsterer J, Soraru G (2016) Onset manifestations of spinal and bulbar muscular atrophy (Kennedy’s disease). J Mol Neurosci 58(3):321–329
Gatchel JR, Zoghbi HY (2005) Diseases of unstable repeat expansion: mechanisms and common principles. Nat Rev Genet 6(10):743–755
Grunseich C, Rinaldi C, Fischbeck KH (2014) Spinal and bulbar muscular atrophy: pathogenesis and clinical management. Oral Dis 20(1):6–9
Halievski K, Mo K, Westwood JT, Monks DA (2015) Transcriptional profile of muscle following acute induction of symptoms in a mouse model of Kennedy’s disease/spinobulbar muscular atrophy. PLoS One 10(2):e0118120
Katsuno M, Adachi H, Doyu M, Minamiyama M, Sang C, Kobayashi Y, Inukai A, Sobue G (2003) Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nat Med 9(6):768–773
Katsuno M, Sang C, Adachi H, Minamiyama M, Waza M, Tanaka F, Doyu M, Sobue G (2005) Pharmacological induction of heat-shock proteins alleviates polyglutamine-mediated motor neuron disease. Proc Natl Acad Sci U S A 102(46):16801–16806
Katsuno M, Tanaka F, Adachi H, Banno H, Suzuki K, Watanabe H, Sobue G (2012) Pathogenesis and therapy of spinal and bulbar muscular atrophy (SBMA). Prog Neurobiol 99(3):246–256
Madeira JL et al (2018) A severe phenotype of Kennedy disease associated with a very large CAG repeat expansion. Muscle Nerve 57(1):E95–E97
Malik B, Nirmalananthan N, Gray AL, la Spada AR, Hanna MG, Greensmith L (2013) Co-induction of the heat shock response ameliorates disease progression in a mouse model of human spinal and bulbar muscular atrophy: implications for therapy. Brain 136(Pt 3):926–943
Mitsumoto H (2017) Long-term treatment with leuprorelin for spinal and bulbar muscular atrophy. J Neurol Neurosurg Psychiatry 88(12):1004–1005
Mohler JL (2018) A brief history of intracrine androgen metabolism by castration-recurrent prostate cancer. Am J Clin Exp Urol 6(2):101–106
Querin G, Bertolin C, da Re E, Volpe M, Zara G, Pegoraro E, Caretta N, Foresta C, Silvano M, Corrado D, Iafrate M, Angelini L, Sartori L, Pennuto M, Gaiani A, Bello L, Semplicini C, Pareyson D, Silani V, Ermani M, Ferlin A, Sorarù G, Italian Study Group on Kennedy's disease (2016) Non-neural phenotype of spinal and bulbar muscular atrophy: results from a large cohort of Italian patients. J Neurol Neurosurg Psychiatry 87(8):810–816
Rhodes LE, Freeman BK, Auh S, Kokkinis AD, la Pean A, Chen C, Lehky TJ, Shrader JA, Levy EW, Harris-Love M, di Prospero NA, Fischbeck KH (2009) Clinical features of spinal and bulbar muscular atrophy. Brain 132(12):3242–3251
Stevic Z, Peric S, Pavlovic S, Basta I, Lavrnic D (2014) Myasthenic symptoms in a patient with Kennedy’s disease. Acta Neurol Belg 114(1):71–73
Wang C, Chen W, Miao D, Yu JT, Tan L (2015) Mitochondrial dysfunction in Kennedy’s disease: a new pharmacological target? Ann Transl Med 3(5):66
Yang Z, Chang YJ, Yu IC, Yeh S, Wu CC, Miyamoto H, Merry DE, Sobue G, Chen LM, Chang SS, Chang C (2007) ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor. Nat Med 13(3):348–353
Acknowledgments
We thank the family members for participating in the study and the referring physicians of the patients.
Funding
This study was supported by grant ZR2013HQ016 from the Natural Scientific Foundation of Shandong Province and grant 2015GGH318011 from the Key Research and Development Project of Shandong Province.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
This retrospective study was approved and supported by the ethical committee of Shandong University, Shandong province, China.
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Liu, X., Zhu, M., Li, X. et al. Clinical manifestations and AR gene mutations in Kennedy’s disease. Funct Integr Genomics 19, 533–539 (2019). https://doi.org/10.1007/s10142-018-0651-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10142-018-0651-7